论文信息 - Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

We read with great interest the recent article by Pardanani et al[1][1] on the treatment of 7 patients (pts) with hypereosinophilic syndrome (HES) and other chronic myeloid disorders associated with eosinophilia (eos-CMD) by imatinib mesylate (Gleevec). In their experience, 2 pts with HES and 1 with

[1] E. Baxter,et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. , 2003, Blood.

[2] K. Kataoka,et al. Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients With Idiopathic Dilated Cardiomyopathy Are Predictive of Adverse Outcomes , 2001, Circulation.

[3] J. Seward,et al. Clinical and echocardiographic features of hypereosinophilic syndromes. , 2000, The American journal of cardiology.

[4] A. Matsumori,et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. , 2000, Internal medicine.

[5] C. Wheatley,et al. Activation of platelets by eosinophil granule proteins , 1990, The Journal of experimental medicine.